Description:
First time in patients study of AZD8835. The study has four parts. Part A AZD8835 is
administered as a single agent in a multiple ascending dose escalation phase to investigate
dose level for monotherapy. Part B follows the multiple ascending dose phase, additional
patients with tumors with documented PIK3CA gene mutation will be enrolled to a single dose
expansion phase. Part C is a second dose escalation phase in which post-menopausal patients
with estrogen receptor positive (ER+), HER2 negative breast cancer will receive AZD8835 in
combination with fulvestrant. Part D follows the combination dose escalation phase of the
study, additional postmenopausal patients with ER+/HER2 negative breast cancer with
documented PIK3CA gene mutation will be enrolled to a AZD8835 and fulvestrant combination
dose-expansion phase at maximum tolerated dose or recommended phase II dose.
Title
- Brief Title: Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours
- Official Title: A Phase I, Open-Label, Multicentre, Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours
Clinical Trial IDs
- ORG STUDY ID:
D6140C00001
- NCT ID:
NCT02260661
Conditions
- Advanced Solid Malignancies
- Breast Cancer - ER+, HER2 -
- Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
Interventions
Drug | Synonyms | Arms |
---|
AZD8835 | | Part A |
AZD8835 | | Part B |
AZD8835 in combination with fulvestrant | Faslodex | Part C |
AZD8835 in combination with fulvestrant | Faslodex | Part D |
Purpose
First time in patients study of AZD8835. The study has four parts. Part A AZD8835 is
administered as a single agent in a multiple ascending dose escalation phase to investigate
dose level for monotherapy. Part B follows the multiple ascending dose phase, additional
patients with tumors with documented PIK3CA gene mutation will be enrolled to a single dose
expansion phase. Part C is a second dose escalation phase in which post-menopausal patients
with estrogen receptor positive (ER+), HER2 negative breast cancer will receive AZD8835 in
combination with fulvestrant. Part D follows the combination dose escalation phase of the
study, additional postmenopausal patients with ER+/HER2 negative breast cancer with
documented PIK3CA gene mutation will be enrolled to a AZD8835 and fulvestrant combination
dose-expansion phase at maximum tolerated dose or recommended phase II dose.
Detailed Description
AZD8835 is a novel small molecule that inhibits cancer progression by blocking PI3 kinase
pathway components p110α and p110δ.
In this first-time-in-patient study, AZD8835 will initially be administered as a single agent
to patients with advanced solid malignancies. Patients will be treated at a starting dose of
20 mg twice daily (BID), administered weekly on Days 1 and 4 and will be escalated to reach a
maximum-tolerated dose (MTD) in patients as defined by dose-limiting toxicities (DLTs). A BID
intermittent dosing schedule administered weekly on Days 1 and 4 of an oral formulation of
AZD8835 will be used, as deemed optimal and effective in non-clinical studies, primarily to
determine the safety and tolerability of AZD8835. The pharmacokinetics (PK) of AZD8835 and
potential biological activity will also be investigated. In Part A of this study, AZD8835
will be administered as a single agent in a multiple ascending dose escalation phase to
investigate the appropriate monotherapy dose level for clinical use. Additional dosing
schedules may be studies, including dosing on Days 1 and 2 of each week, rather than Days 1
and 4.
Backfilled pharmacodynamic (PDc) cohorts in selected patients with tumours that have
documented mutations in the phosphatidylinositol-4,5- bisphosphate 3-kinase, catalytic
subunit alpha (PIK3CA) gene will allow further preliminary assessment of the biological
effect of AZD8835 in these patients.
Following the single-agent dose-escalation phase of the study, additional patients with
tumours that have documented mutations in the PIK3CA gene will be enrolled to a single-agent
dose-expansion phase at the MTD or recommended Phase II dose (RP2D) at the selected dose
schedule (as appropriate) to explore further the safety, tolerability, PK, and biological
activity at the selected dose (Part B).
In addition, a further dose-escalation phase will be initiated following the observation of
specific pre-determined criteria in the single-agent dose escalation, in which postmenopausal
patients with oestrogen receptor positive (ER+), HER2 negative breast cancer will receive
AZD8835 in combination with fulvestrant (Part C). The combination dose-escalation phase will
investigate the appropriate combination dose level for clinical use.
Following the combination dose-escalation phase of the study, additional postmenopausal
patients with ER+ breast cancer and tumours with documented mutations of the PIK3CA gene will
be enrolled to a AZD8835 and fulvestrant combination dose-expansion phase at the MTD or RP2D
(as appropriate) to explore further the safety, tolerability, PK, and biological activity at
the selected dose (Part D).
Trial Arms
Name | Type | Description | Interventions |
---|
Part A | Experimental | AZD8835 single agent dose escalation | |
Part B | Experimental | Following the single agent dose escalation (Part A), additional patients with mutations in the PIK3CA gene will be enrolled to a single agent dose expansion phase at the MTD or recommended phase II dose (RP2D) at the selected dose schedule (as appropriate) to explore further the safety, tolerability, pharmacokinetics and biological activity at the selected dose (Part B). Part B will include patients with ER+/HER2 negative breast cancer whose tumours have a mutation of the PIK3CA gene and patients with any solid tumours which have a mutation of the PIK3CA gene. | |
Part C | Experimental | AZD8835 in combination with fulvestrant dose escalation | - AZD8835 in combination with fulvestrant
|
Part D | Experimental | Following the combination dose escalation segment of the study (Part C), additional postmenopausal patients with ER+/HER negative breast cancer and mutations of the PIK3CA gene will be enrolled to a AZD8835 and fulvestrant combination dose expansion phase at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) (as appropriate) to explore further the safety, tolerability, pharmacokinetics and biological activity at the selected dose (Part D). | - AZD8835 in combination with fulvestrant
|
Eligibility Criteria
Inclusion Criteria:
1. Part A: Histological or cytological confirmation of a solid tumor and disease
progression. Part B: Histological or cytological confirmation of ER positive, HER2
negative breast cancer and disease progression or any other solid tumor with a PIK3CA
gene mutation. Part C: Histological or cytological confirmation of ER positive, HER2
negative postmenopausal breast cancer with locally advanced or metastatic disease that
is eligible for fulvestrant treatment. Part D: Histological or cytological
confirmation of ER positive, HER2 negative postmenopausal breast cancer with locally
advanced or metastatic disease that is eligible for fulvestrant treatment. Patients
must also present with a tumor related mutation of the PIK3CA gene.
2. Availability of archival tumour tissue sample. If archival sample is not available, a
fresh tumour biopsy must be provided.
3. At least one measurable lesion per RECIST v1.1. However, breast cancer patients with
only bone disease are also eligible.
4. ECOG Performance Status 0-1.
5. Adequate organ function at baseline:
1. Serum total bilirubin ≤ 1.5 x ULN and AST/SGOT and ALT/SGPT ≤ 2.5 x ULN or ≤ 5 x
ULN if liver metastases are present.
2. Creatinine ≤ 1.5 x ULN, or calculated or measured creatinine clearance ≥ 50
mL/min, or 24-hour measured urine creatinine clearance ≥ 50 mL/min.
3. Platelets ≥ 100 x 10^9, Hb ≥ 90 g/L, ANC ≥ 1.5 x 10^9/L.
4. aPTT ≤ 1.5 x ULN
5. Fasting glucose < 140 mg/dL (7.8 mmol/L).
6. Glycated haemoglobin (HbA1c) < 8%
6. Female patients and male patients with female partners of child bearing potential must
be using adequate contraception.
Exclusion Criteria:
1. Recent chemotherapy, radiotherapy, hormonal therapy, immunotherapy or investigational
drugs within 21 days or 5 half-days from enrolment.
2. Received palliative/focal radiotherapy within 2 weeks of first dose of study
treatment.
3. Major surgery ≤ 21 days from beginning of study drug
4. Any of the following cardiac criteria: CHF > Class II, cardiac ventricular arrhythmia
requiring therapy, unstable angina or new-onset angina, QTcF interval >470ms, abnormal
ECHO or MUGA at baseline (LVEF <50%).
5. Leptomeningeal disease
6. Part A: Intolerable AEs due to other PI3K inhibitors, dual PI3K and mTOR inhibitors or
AKT inhibitors. Parts B, C, and D: Prior exposure to any of the following:
pharmacological inhibitors of AKT, PI3K, or dual PI3K and mTOR kinase activity
7. Strong inhibitors and potent inducers of CYP3A4
8. Peripheral neuropathy CTCAE v4.03 Grade ≥ 3
9. Diarrhoea CTCAE v4.03 Grade ≥ 2
10. Acute or chronic pancreatitis
11. Clinically manifest diabetes mellitus, history of gestational diabetes mellitus and/or
known glucose intolerance.
12. Patients currently receiving any medication that has the potential to prolong the QT
interval or induce Torsades de Pointes
13. Spinal cord compression or brain metastases unless asymptomatic and not requiring
steroids for at least 4 weeks
14. Patients in the combination arms - known hypersensitivity to fulvestrant
15. Therapeutic treatment with Coumadin or any other coumarin-derivative anticoagulant
16. Impaired GI function or GI disease that may interfere with absorption of AZD8835 or
patients unable to take oral medication
17. As judged by the investigator any evidence of severe or uncontrolled systemic disease
18. Patients treated with hematopoietic colony-stimulating growth factors e.g., G-CSF,
GM-CSF, M-CSF) ≤ 2 weeks prior to start. Erythropoietin or darbepoetin is allowed if
it was initiated at least 2 weeks prior to entry
Maximum Eligible Age: | 130 Years |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Determine the maximum tolerated dose (MTD) or recommended Phase II dose of oral AZD8835 as a single agent and in combination with fulvestrant |
Time Frame: | At the end of one cycle of treatment |
Safety Issue: | |
Description: | MTD - A dose will be considered non-tolerated and dose escalation will stop if 2 or more of up to 6 evaluable patients experience a dose limiting toxicity at a dose level. Once the non-tolerated dose is defined, the MTD will be confirmed at the previous dose level below the non-tolerated dose or a dose between the non-tolerated dose and the last tolerated dose my be investigated. A minimum of 6 evaluable patients are required to determine the MTD. Recommended Phase II dose - A minimum of 6 evaluable patients is necessary to determine the recommended dose. A dose will be considered non-tolerated and dose escalation will stop if 2 or more patients experience a dose dose limiting toxicity at a dose level. |
Secondary Outcome Measures
Measure: | To establish the pharmacokinetic profile of oral AZD8835 as a single agent and in combination with fulvestrant |
Time Frame: | Venous blood samples will be collected pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 96 hours post dose - exact schedule varies according to Part A, B, C, or D |
Safety Issue: | |
Description: | Venous blood samples (2 mL) for determination of concentrations of AZD8835 and the investigation of AZ8835 metabolites in plasma will be taken during Parts A, B, C, D |
Measure: | To evaluate the preliminary efficacy and anti-tumor activity of oral AZD8835 as a single agent or in combination with fulvestrant |
Time Frame: | Tumour response will be assessed at the completion of Cycle 2 (Week 8) and patients will be restaged after every 8 weeks for up to 1 year and every 12 weeks thereafter; assessments should be performed until disease progression. |
Safety Issue: | |
Description: | Categorization of objective tumor response will be based on RECIST v1.1 guidelines for complete response, partial response, stable disease, or progression of disease |
Measure: | To evaluate the pharmacodynamic (PDc) effect of oral AZD8835 as a single agent and in combination with fulvestrant |
Time Frame: | Tumour biopsies will be collected: (1) at pretreatment, (2) at one on-treatment time point (preferably Cycle 2 Day 1), and (3) at end of study treatment (preferably at disease progression) |
Safety Issue: | |
Description: | Tumor samples will be analyzed to assess PRAS40 phosphorylation, AKT phosphorylation, S6 phosphorylation, FOXO3a localisation |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Completed |
Lead Sponsor: | AstraZeneca |
Trial Keywords
- AZD8835
- Fulvestrant
- Breast Cancer
- PIK3CA Gene Mutation
Last Updated
October 10, 2016